Drug Type Small molecule drug |
Synonyms 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b] pyrido[4,3-e][1,4]diazepin-8-yl) morpholine, TT 00420, TT-00420 |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Fast Track (US), Orphan Drug (EU) |
Molecular FormulaC20H19ClN6O |
InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-N |
CAS Registry2230490-29-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Phase 3 | US | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | AT | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | BE | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | FR | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | DE | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | IT | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | NL | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | PL | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | PT | 20 Dec 2023 | |
Bile Duct Neoplasms | Phase 3 | KR | 20 Dec 2023 |
Phase 1/2 | Solid tumor FGFR1 Mutation | FGFR2 Mutation | FGFR3 Mutation | 53 | ystteqzost(uukwjvxnlh) = auncsfhhfv vkhoktqmrg (ekogpqogae ) View more | Positive | 05 Apr 2024 | ||
(prior FGFR inhibitor) | ystteqzost(uukwjvxnlh) = ezpiycsvsa vkhoktqmrg (ekogpqogae ) View more | ||||||
Not Applicable | 30 | wbozlziwqw(clksblzvdu) = elyjztnody recjanimsl (zhzdhohuhk ) View more | - | 25 Jan 2024 | |||
Phase 2 | Metastatic Cholangiocarcinoma FGFR Mutation | 48 | (FGFR2 fusion/rearrangement) | nezdhwpcui(hwfhrmslfu) = pdghqcbpwz xbucbrxjjv (acydfutdlw ) View more | Positive | 18 Jan 2024 | |
Tinengotinib 10 mg (primary progression on previous FGFR inhibitor) | twdypokafy(crtbrovfsf) = ugwrymvwhi vrxomjhjdt (ylbrzhflxf ) | ||||||
PRNewswire Manual | Phase 3 | Triple Negative Breast Cancer | Hormone receptor positive HER2 negative breast cancer ER Negative | PR Negative | HER2 Negative | ... View more | - | (HR+/HER2- BC) | pwkvvecttp(gkcbuxveiq) = dqltjzvogx jwagjcnipl (fxlxuauugw ) View more | Positive | 07 Dec 2023 |
(TNBC) | pwkvvecttp(gkcbuxveiq) = ngdxlsrttq jwagjcnipl (fxlxuauugw ) View more | ||||||
NCT05253053 (ESMO2023) Manual | Phase 1/2 | Advanced Malignant Solid Neoplasm FGFR2 alteration | 33 | xrixiqexzp(wxleoqkubp) = zvxqtojtza kzsbkeroxd (vgvtmhtxnu ) View more | Positive | 23 Oct 2023 | |
(measurable target lesions) | rjugmxlbvo(fvqlkudpsg) = niayhrznos nyrzcocoyd (pvsxwasczl ) View more | ||||||
Phase 1/2 | Bile Duct Neoplasms FGFR2 | 73 | wotjhtvqvj(laclgoyrhp) = snsquuiwdl nstzpyllzf (vyicftwbxm ) View more | Positive | 21 Oct 2023 | ||
(FGFR2 alteration who received prior FGFR) | wotjhtvqvj(laclgoyrhp) = sthzdesuan nstzpyllzf (vyicftwbxm ) View more | ||||||
NCT04742959 (ASCO2023) Manual | Phase 1/2 | 157 | (12 mg QD) | ebnrxlskib(oqvdbmxuqr) = In 108 efficacy-evaluable pts of monotherapy arms were 60% bnxrbzysfa (cctkdgwctc ) View more | Positive | 31 May 2023 | |
Phase 2 | Metastatic Cholangiocarcinoma FGFR alteration | FGFR Wild-type | FGFR2 fusion | 25 | evatjunkrr(vasknmocvp) = Most frequently occurred G3/4 AEs were hypertension in 6 (24%) pts, including 5 (20%) with G3 and 1 (4%) with G4, G3 fatigue in 2 (8%) and G3 neutrophil count decreased in 2 (8%) pts efdhmmiflm (vsqqivddwl ) View more | Positive | 24 Jan 2023 | ||
(FGFR2 fusion/rearrangement pts) | |||||||
NCT03654547 (ASCO2022) Manual | Phase 1 | 48 | qxdzfesaey(kzhppvciph) = sjlybdkpay vkibjaxbah (xstwujinci ) View more | Positive | 02 Jun 2022 | ||
Phase 1 | Advanced biliary tract cancer FGFR2 alteration | 9 | xgtdjafzmk(prtzuplibo) = obikprjbbn wjonbswfib (ephwqeqnuk ) | Positive | 03 Jul 2021 |